Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, Dipersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK (2019)


Publication Type: Journal article

Publication year: 2019

Journal

Book Volume: 54

Pages Range: 1868-1880

Journal Issue: 11

DOI: 10.1038/s41409-019-0451-2

Abstract

On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring and disease assessments. To address these issues, experts representing the American Society for Blood and Marrow Transplant (ASBMT), the European Group for Blood and Marrow Transplantation (EBMT), the International Society of Cell and Gene Therapy (ISCT), and the Foundation for the Accreditation of Cellular Therapy (FACT), formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.

Involved external institutions

University of Texas Southwestern Medical Center (UT Southwestern) US United States (USA) (US) University of Pennsylvania US United States (USA) (US) University of Washington US United States (USA) (US) Vanderbilt University US United States (USA) (US) UHealth Tower, University of Miami Health System US United States (USA) (US) University of Minnesota (UMN) US United States (USA) (US) University of Texas MD Anderson Cancer Center US United States (USA) (US) Chaim Sheba Medical Center at Tel HaShomer / המרכז הרפואי עש חיים שיבא – תל השומר‎‎ IL Israel (IL) Stanford University US United States (USA) (US) Memorial Sloan Kettering Cancer Center US United States (USA) (US) Mayo Clinic US United States (USA) (US) Aix-Marseille University / Aix-Marseille Université FR France (FR) Cornell University US United States (USA) (US) Universitätsklinikum Würzburg DE Germany (DE) King Faisal Specialist Hospital & Research Centre SA Saudi Arabia (SA) Ohio State University US United States (USA) (US) George Washington University (GWU) US United States (USA) (US) Università Vita-Salute San Raffaele (UniSR) IT Italy (IT) Washington University in St. Louis US United States (USA) (US) H. Lee Moffitt Cancer Center & Research Institute US United States (USA) (US) National Cancer Institute (NCI) US United States (USA) (US) King’s College London GB United Kingdom (GB) American University of Beirut (AUB) / الجامعة الأميركية في بيروت‎‎ LB Lebanon (LB) University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne FR France (FR) The Methodist Hospital System US United States (USA) (US) Children’s National Health System US United States (USA) (US)

How to cite

APA:

Kansagra, A.J., Frey, N.V., Bar, M., Laetsch, T.W., Carpenter, P.A., Savani, B.N.,... Hashmi, S.K. (2019). Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation, 54(11), 1868-1880. https://doi.org/10.1038/s41409-019-0451-2

MLA:

Kansagra, Ankit J., et al. "Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)." Bone Marrow Transplantation 54.11 (2019): 1868-1880.

BibTeX: Download